Tina Z Khan1,2, Li-Yueh Hsu3, Andrew E Arai3, Samantha Rhodes4, Alison Pottle4, Ricardo Wage4, Winston Banya4, Peter D Gatehouse1,2, Shivraman Giri5, Peter Collins1,2, Dudley J Pennell1,2, Mahmoud Barbir1,2. 1. NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. 2. National Heart and Lung Institute, Imperial College, Sydney Street, London SW3 6NP, UK. 3. National Heart, Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA. 4. NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3?6NP, UK. 5. Siemens Healthcare, 737 North Michigan Ave, Chicago, IL 60611, USA.
Abstract
AIMS: To determine the clinical impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a) > 500 mg/L on the primary end point of quantitative myocardial perfusion, as well as secondary end points including atheroma burden, exercise capacity, symptoms, and quality of life. METHODS: We conducted a single-blinded randomized controlled trial in 20 patients with refractory angina and raised lipoprotein(a) > 500 mg/L, with 3 months of blinded weekly lipoprotein apheresis or sham, followed by crossover. The primary endpoint was change in quantitative myocardial perfusion reserve (MPR) assessed by cardiovascular magnetic resonance. Secondary endpoints included measures of atheroma burden, exercise capacity, symptoms and quality of life. RESULTS: The primary endpoint, namely MPR, increased following apheresis (0.47; 95% CI 0.31-0.63) compared with sham (-0.16; 95% CI - 0.33-0.02) yielding a net treatment increase of 0.63 (95% CI 0.37-0.89; P < 0.001 between groups). Improvements with apheresis compared with sham also occurred in atherosclerotic burden as assessed by total carotid wall volume (P < 0.001), exercise capacity by the 6 min walk test (P = 0.001), 4 of 5 domains of the Seattle angina questionnaire (all P < 0.02) and quality of life physical component summary by the short form 36 survey (P = 0.001). CONCLUSION: Lipoprotein apheresis may represent an effective novel treatment for patients with refractory angina and raised lipoprotein(a) improving myocardial perfusion, atheroma burden, exercise capacity and symptoms. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To determine the clinical impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a) > 500 mg/L on the primary end point of quantitative myocardial perfusion, as well as secondary end points including atheroma burden, exercise capacity, symptoms, and quality of life. METHODS: We conducted a single-blinded randomized controlled trial in 20 patients with refractory angina and raised lipoprotein(a) > 500 mg/L, with 3 months of blinded weekly lipoprotein apheresis or sham, followed by crossover. The primary endpoint was change in quantitative myocardial perfusion reserve (MPR) assessed by cardiovascular magnetic resonance. Secondary endpoints included measures of atheroma burden, exercise capacity, symptoms and quality of life. RESULTS: The primary endpoint, namely MPR, increased following apheresis (0.47; 95% CI 0.31-0.63) compared with sham (-0.16; 95% CI - 0.33-0.02) yielding a net treatment increase of 0.63 (95% CI 0.37-0.89; P < 0.001 between groups). Improvements with apheresis compared with sham also occurred in atherosclerotic burden as assessed by total carotid wall volume (P < 0.001), exercise capacity by the 6 min walk test (P = 0.001), 4 of 5 domains of the Seattle angina questionnaire (all P < 0.02) and quality of life physical component summary by the short form 36 survey (P = 0.001). CONCLUSION: Lipoprotein apheresis may represent an effective novel treatment for patients with refractory angina and raised lipoprotein(a) improving myocardial perfusion, atheroma burden, exercise capacity and symptoms. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano Journal: Eur Heart J Date: 2013-08-30 Impact factor: 29.983
Authors: Ronen Rubinshtein; Jeffrey T Kuvin; Morgan Soffler; Ryan J Lennon; Shahar Lavi; Rebecca E Nelson; Geralyn M Pumper; Lilach O Lerman; Amir Lerman Journal: Eur Heart J Date: 2010-02-24 Impact factor: 29.983
Authors: Josef Leebmann; Eberhard Roeseler; Ulrich Julius; Franz Heigl; Ralf Spitthoever; Dennis Heutling; Paul Breitenberger; Winfried Maerz; Walter Lehmacher; Andreas Heibges; Reinhard Klingel Journal: Circulation Date: 2013-09-20 Impact factor: 29.690
Authors: Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum Journal: Lancet Date: 2015-07-22 Impact factor: 79.321
Authors: Christopher M Kramer; Jörg Barkhausen; Scott D Flamm; Raymond J Kim; Eike Nagel Journal: J Cardiovasc Magn Reson Date: 2013-10-08 Impact factor: 5.364
Authors: Adrian S H Cheng; Tammy J Pegg; Theodoros D Karamitsos; Nick Searle; Michael Jerosch-Herold; Robin P Choudhury; Adrian P Banning; Stefan Neubauer; Matthew D Robson; Joseph B Selvanayagam Journal: J Am Coll Cardiol Date: 2007-06-11 Impact factor: 24.094
Authors: Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu Journal: J Am Coll Cardiol Date: 2018-01-16 Impact factor: 24.094
Authors: Melinda D Wu; Federico Moccetti; Eran Brown; Brian P Davidson; Tamara Atkinson; J Todd Belcik; George Giraud; P Barton Duell; Sergio Fazio; Hagai Tavori; Sotirios Tsimikas; Jonathan R Lindner Journal: JACC Cardiovasc Imaging Date: 2018-06-19
Authors: Vassilios S Vassiliou; Paul D Flynn; Claire E Raphael; Simon Newsome; Tina Khan; Aamir Ali; Brian Halliday; Annina Studer Bruengger; Tamir Malley; Pranev Sharma; Subothini Selvendran; Nikhil Aggarwal; Anita Sri; Helen Berry; Jackie Donovan; Willis Lam; Dominique Auger; Stuart A Cook; Dudley J Pennell; Sanjay K Prasad Journal: PLoS One Date: 2017-07-13 Impact factor: 3.240
Authors: Jonathan Golledge; Sophie Rowbotham; Ramesh Velu; Frank Quigley; Jason Jenkins; Michael Bourke; Bernie Bourke; Shivshankar Thanigaimani; Dick C Chan; Gerald F Watts Journal: J Am Heart Assoc Date: 2020-03-14 Impact factor: 5.501
Authors: Juha Hartikainen; Iiro Hassinen; Antti Hedman; Antti Kivelä; Antti Saraste; Juhani Knuuti; Minna Husso; Hanna Mussalo; Marja Hedman; Tuomas T Rissanen; Pyry Toivanen; Tommi Heikura; Joseph L Witztum; Sotirios Tsimikas; Seppo Ylä-Herttuala Journal: Eur Heart J Date: 2017-09-01 Impact factor: 29.983